摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-Benzyloxy-3-chloro-phenyl)-(4,6-dichloro-[1,3,5]triazin-2-yl)-amine | 866769-11-1

中文名称
——
中文别名
——
英文名称
(4-Benzyloxy-3-chloro-phenyl)-(4,6-dichloro-[1,3,5]triazin-2-yl)-amine
英文别名
4,6-dichloro-N-(3-chloro-4-phenylmethoxyphenyl)-1,3,5-triazin-2-amine
(4-Benzyloxy-3-chloro-phenyl)-(4,6-dichloro-[1,3,5]triazin-2-yl)-amine化学式
CAS
866769-11-1
化学式
C16H11Cl3N4O
mdl
——
分子量
381.649
InChiKey
LIQVNNXUWRXDAB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.9
  • 重原子数:
    24
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    59.9
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Methods and compositions of novel triazine compounds
    摘要:
    本发明涉及治疗由炎症反应引起的病理生理条件的方法和组合物,具体而言,本发明涉及抑制或阻断糖化蛋白诱导内皮细胞中信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物,具体而言,本发明涉及通过调节HSPGs(如Perlecan)来抑制平滑肌细胞增殖的化合物。本发明还涉及利用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病,如再狭窄和动脉粥样硬化。
    公开号:
    US20040209882A1
  • 作为产物:
    描述:
    三聚氯氰4-benzyloxy-3-chloroanilinesodium hydroxide 作用下, 以 丙酮 为溶剂, 反应 1.0h, 以60%的产率得到(4-Benzyloxy-3-chloro-phenyl)-(4,6-dichloro-[1,3,5]triazin-2-yl)-amine
    参考文献:
    名称:
    Triazine compounds and their analogs, compositions, and methods
    摘要:
    本发明涉及三嗪化合物及其类似物和衍生物,以及包含这些化合物的方法和组合物。本发明的化合物和组合物可用于治疗由炎症反应引起的病理生理条件,抑制或阻断糖化蛋白诱导内皮细胞中与信号相关的炎症反应,抑制平滑肌增殖,治疗以平滑肌增殖为特征的血管闭塞性疾病,如再狭窄和动脉粥样硬化等。
    公开号:
    US20050227983A1
点击查看最新优质反应信息

文献信息

  • Methods and compositions of novel triazine compounds
    申请人:——
    公开号:US20040209881A1
    公开(公告)日:2004-10-21
    The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.
    本发明涉及治疗由炎症反应引起的病理生理状况的方法和组合物,具体而言,本发明涉及抑制或阻断糖化蛋白诱导内皮细胞中与信号相关的炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物,具体而言,本发明涉及通过调节HSPGs(如Perlecan)来抑制平滑肌细胞增殖的化合物。本发明还涉及利用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病,如再狭窄和动脉粥样硬化。
  • US7335770B2
    申请人:——
    公开号:US7335770B2
    公开(公告)日:2008-02-26
  • [EN] TRIAZINE COMPOUNDS AND THEIR ANALOGS, COMPOSITIONS, AND METHODS<br/>[FR] COMPOSES A BASE DE TRIAZINE ET LEURS ANALOGUES, COMPOSITIONS, ET PROCEDES
    申请人:REDDY US THERAPEUTICS INC
    公开号:WO2005103015A1
    公开(公告)日:2005-11-03
    The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.
  • Triazine compounds and their analogs, compositions, and methods
    申请人:Timmer T. Richard
    公开号:US20050227983A1
    公开(公告)日:2005-10-13
    The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.
    本发明涉及三嗪化合物及其类似物和衍生物,以及包含这些化合物的方法和组合物。本发明的化合物和组合物可用于治疗由炎症反应引起的病理生理条件,抑制或阻断糖化蛋白诱导内皮细胞中与信号相关的炎症反应,抑制平滑肌增殖,治疗以平滑肌增殖为特征的血管闭塞性疾病,如再狭窄和动脉粥样硬化等。
查看更多